Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alamar BiosciencesALMR +1.24%8 Cash Ratio is 1.26 as of Dec. 2025, which is 58% below its 10-year median of 3.02. GuruFocus rates ALMR with a GF Score™ of 8/100. The stock has 1 warning sign investors should review. Among 841 Medical Devices & Instruments companies, Alamar Biosciences ranks better than 56% on this metric.
Alamar Biosciences has a Cash Ratio of 1.26. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Alamar Biosciences's Cash Ratio or its related term are showing as below:
ALMR'
s Cash Ratio Range Over the Past 10 Years
Min: 1.26 Med: 3.02 Max: 4.78
Current: 1.26
During the past 2 years, Alamar Biosciences's highest Cash Ratio was 4.78. The lowest was 1.26. And the median was 3.02.
ALMR's Cash Ratio is ranked better than 56% of 841
companies
in the Medical Devices & Instruments industry
Industry Median: 0.97
vs ALMR: 1.26
Alamar Biosciences (NAS:ALMR) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Alamar Biosciences Cash Ratio Related Terms
Alamar Biosciences Cash Ratio Historical Data
* Premium members only.
The historical data trend for Alamar Biosciences's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alamar Biosciences Cash Ratio Chart
Alamar Biosciences Annual Data
Trend
Dec24
Dec25
Cash Ratio
4.78
1.26
Alamar Biosciences Semi-Annual Data
Dec24
Dec25
Cash Ratio
4.78
1.26
ALMR vs UFPT, BFLY, ENOV: Cash Ratio Comparison
For the Medical Devices subindustry, Alamar Biosciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alamar Biosciences Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Alamar Biosciences's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Alamar Biosciences's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alamar Biosciences (ALMR) has a Cash Ratio of 1.26 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Alamar Biosciences and its competitors. This is 58% below median its historical median of 3.02. Over the past decade, Alamar Biosciences' Cash Ratio has ranged from 1.26 to 4.78. According to the industry distribution chart, Alamar Biosciences ranks #370 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 44%.
Is Alamar Biosciences' Cash Ratio too high?
Alamar Biosciences' current Cash Ratio of 1.26 is 58% below median its 10-year median of 3.02. Over the past 10 years, this metric has ranged from a low of 1.26 to a high of 4.78. The Medical Devices & Instruments industry median Cash Ratio is 0.97. Alamar Biosciences' value of 1.26 is 29.9% above this industry median. Based on the distribution chart, Alamar Biosciences ranks #370 out of 841 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Alamar Biosciences has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Alamar Biosciences' Cash Ratio compare to UFPT and BFLY?
According to the Medical Devices & Instruments industry distribution chart, Alamar Biosciences ranks #370 out of 841 companies for Cash Ratio. This puts Alamar Biosciences in the upper half of its industry. The industry median Cash Ratio is 0.97. Alamar Biosciences' value of 1.26 is 29.9% above this benchmark. Historically, Alamar Biosciences' own Cash Ratio has ranged from 1.26 to 4.78 over the past decade. While the company's 10-year median is 3.02 vs. the industry median of 0.97, Alamar Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.97, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alamar Biosciences's current Cash Ratio of 1.26 is 29.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Alamar Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alamar Biosciences's current Cash Ratio is 1.26, which is 58% below median its own 10-year median of 3.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alamar Biosciences stock overvalued right now?
Alamar Biosciences (ALMR) has a current Cash Ratio of 1.26. The current Cash Ratio is 1.26, which is 58% below median its 10-year median of 3.02 and 29.9% above the Medical Devices & Instruments industry median of 0.97. Alamar Biosciences' overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Alamar Biosciences (ALMR), the current Cash Ratio is 1.26 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
8GF Score
Get the complete analysis for ALMR
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALMR has been successfully added to your 
